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Nitric Oxide–Induced Downregulation of Cdk2 Activity and
Cyclin A Gene Transcription in Vascular
Smooth Muscle Cells
Kun Guo, PhD; Vicente Andre´s, PhD; Kenneth Walsh, PhD
Background—Nitric oxide (NO) inhibits vascular smooth muscle cell (VSMC) proliferation and neointima formation after
balloon injury. However, the molecular mechanisms underlying NO-mediated growth arrest are poorly understood. In
the present study, we examined the effects of the NO donors sodium nitroprusside (SNP) and S-nitroso-N-
acetylpenicillamine (SNAP) on cell cycle activity in VSMCs.
Methods and Results—Stimulation of quiescent rat VSMCs with serum leads to an increase in cyclin-dependent kinase
(cdk)2 kinase activity that correlates with a marked induction of cyclin A protein expression. The addition of SNP or
SNAP to VSMC cultures at the time of serum stimulation abrogates the induction of cdk2 activity without suppressing
protein levels of cdk2 or cyclin E. These NO donors block serum-stimulated upregulation of cyclin A mRNA and protein
and repress the serum induction of cyclin A promoter activity in VSMCs.
Conclusions—The addition of the nitric oxide donors SNP or SNAP to mitogen-stimulated VSMCs prevents
activation of cdk2, a key regulator of the G1 and S phases of the cell cycle. These NO donors do not affect the
expression of cdk2 protein but block the mitogen-induced expression of cyclin A, an activating subunit of cdk2.
SNP and SNAP also repress the mitogen-stimulated activation of the cyclin A promoter. These data suggest that
the antiproliferative effect of NO on VSMCs results, at least in part, from the repression of cyclin A gene
transcription. (Circulation. 1998;97:2066-2072.)
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Vascular smooth muscle cell proliferation contributes tothe restenotic lesion that develops after balloon angio-
plasty1 and is of major importance in the development of
in-stent restenosis2–4 and bypass graft occlusion.5 NO is
released from the endothelium and is believed to function as
a physiological regulator of vessel tone and VSMC prolifer-
ation.6,7 The restoration of endothelial cell NO synthase
activity in denuded rat carotid arteries through gene transfer
results in increased vascular reactivity and a reduction in
neointima formation.8 Likewise, the long-term oral adminis-
tration or the acute intramural administration of L-arginine, a
precursor of NO, enhances vascular NO activity and reduces
the size of vascular lesions that result from injury on
hypercholesterolemia.9–13 Despite the widely recognized in-
volvement of NO in the regulation of VSMC proliferation,
the molecular mechanisms underlying NO-mediated VSMC
growth arrest are poorly understood.
Cell cycle progression is regulated by the periodic activa-
tion of a family of cdks. Activation of cdks requires their
association with specific cyclin regulatory subunits.14,15 The
cdk2/cyclin E and cdk2/cyclin A holoenzymes are important
regulators of the G1 and S phases of the cell cycle, respec-
tively. Microinjection of anti–cyclin E antibody prevents
fibroblasts from entering S phase,16 and overexpression of
cyclin E induces the phosphorylation of the retinoblastoma
protein and shortens the G1 phase.17–19 Cyclin A expression
typically peaks in S phase and is required for DNA replication
and progression through S phase.20–23 Previously, we demon-
strated the induction of cdk2/cyclin E and cdk2/cyclin A
complexes during the fibroproliferative response to balloon
injury in the rat carotid artery,24 and others have shown that
antisense cdk2 oligonucleotides inhibit neointima
formation.25,26
In the present study, we tested the hypothesis that the
antiproliferative effect of NO in VSMCs is mediated, at least
in part, by the inhibition of cdk2 activity. The addition of the
NO donors SNP or SNAP to VSMCs effectively inhibited
mitogen-stimulated cdk2 activity, but this treatment had no
effect on cdk2 protein levels. NO donors did not alter cyclin
E expression levels, but they blocked the induction of cyclin
A by mitogens. These donors also blocked the mitogen
induction of cyclin A mRNA and promoter activity; there-
fore, these data suggest that the transcriptional repression of
cyclin A gene is one mechanism by which NO inhibits
VSMC proliferation.
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Methods
cdk2 Assay
Primary rat aortic VSMCs were isolated essentially as described
by Mader et al.27 Cultures were serum starved for 24 hours in
DMEM supplemented with 0.5% FBS, after which cells were
switched to DMEM supplemented with 10% FBS for 18, 36, or 48
hours with or without the presence of the indicated amount of
SNAP or SNP. Cells were lysed in lysis buffer (50 mmol/L Tris,
pH 8.0, 250 mmol/L NaCl, 0.5% Nonidet P-40, 1 mg/mL
leupeptin, 1 mmol/L phenylmethylsulfonyl fluoride). Insoluble
materials were cleared through centrifugation at 4°C for 10
minutes at 12 000 rpm. Protein concentrations were determined
with the Bradford assay (BioRad). For cdk2 kinase assay, 20 mg
of protein extracts was precleared with Protein A agarose, after
which 0.5 mg of anti-cdk2 antibodies (Santa Cruz Biotechnology)
were added, incubated for 2 hours, and precipitated by the
addition of Protein A agarose. After being washed three times
with lysis buffer and three times with cdk2 kinase buffer
(250 mmol/L Tris, pH 7.6, 10 mmol/L MgCl2, 1 mmol/L
dithiothreitol), kinase activity of the immunopellets was assayed
with the use of histone H1 as substrate (2 mg histone H1,
10 mmol/L ATP, 4 mCi [g-32P]ATP in kinase buffer) at room
temperature for 30 minutes. After electrophoresis with SDS-12%
polyacrylamide gels, the gels were exposed to fixative solution
(10% methanol, 10% acetic acid) for 30 minutes and dried. Gels
were exposed to Kodak X-ray film overnight.
Western Blotting
Fifty micrograms of protein extracts was subjected to Western
blotting with the use of anti-cdk2, anti– cyclin A, anti– cyclin E,
or anti-tubulin antibodies (Santa Cruz Biotechnology) as de-
scribed previously.28 Briefly, proteins were separated in SDS-12%
polyacrylamide gels and transferred to membranes. Blots were
incubated in 5% nonfat dry milk (in 13 PBS, 0.2% Tween 20) for
2 hours at room temperature and were incubated with the
indicated antibodies (1:200 dilution in 2% nonfat dry milk, 0.2%
Tween 20 in 13 PBS) for 3 hours. After three washes in 2%
nonfat dry milk and 0.2% Tween 20 in 13 PBS (10 minutes
each), blots were incubated with horseradish perioxidase– conju-
gated secondary antibodies (1:2000 dilution) for 40 minutes.
After three washes with 2% nonfat dry milk (in 13 PBS plus
0.2% Tween 20 for 10 minutes each) and three washes in 13 PBS
plus 0.2% polyoxyethylene sorbitan monolaurate (5 minutes
each), immunocomplexes were detected using the enhanced
chemiluminescence system according to the recommendations of
the manufacturer (Amersham).
Northern Blotting
Northern blot analysis was performed with 20 mg of total RNA
prepared with the use of RNAzol B (Biotecx Laboratories, Inc) as
described previously.28 After transfer to a Hybond-N membrane
(Amersham) and UV cross-linking, the blot was hybridized with
a human cyclin A cDNA probe generated by random primer
labeling (Boehringer-Mannheim Biochemicals) according to the
manufacturer’s instructions. After hybridization, the blots were
washed for 20 minutes at 65°C in 0.23 SSC (13 SSC is 0.15
mol/L NaCl plus 0.015 mol/L sodium citrate)/0.1% SDS and
exposed to Kodak X-ray film.
Transient Transfection
Cyclin A promoter-luciferase constructs contain the human
2924/1245 and 279/1100 cyclin A promoter regions.29 The
254/1100 cyclin A–luciferase reporter was generated with the
polymerase chain reaction with specific primers containing KpnI
and BglI restriction sites and subcloned into KpnI/BglI– digested
pGL2 Basic (Promega). The Simian virus 40 promoter–alkaline
phosphatase reporter construct, pSV2-AP, contains the reporter
gene under the control of the Simian virus 40
promoter-enhancer.30
Before transfections, PAC1 cells31 were serum starved in
DMEM supplemented with 0.5% FBS for 24 hours. Transfections
were carried out with Lipofectamine (GIBCO Laboratories)
according to the manufacturer’s instructions. Briefly, DNA and
Lipofectamine were mixed together for 40 minutes in OptiMem
medium (GIBCO) and incubated with cells in OptiMem medium
for 3 hours. After transfection, cells were switched to DMEM
supplemented with 0.5% FBS or DMEM supplemented with 10%
FBS with or without the indicated amount of 8-Br-cGMP, SNAP,
or SNP for 20 hours. Cells were harvested in 13 lysis buffer
(Promega) and assayed for luciferase and alkaline phosphatase
activity, as described previously.32,33 Reporter gene activity was
recorded with a Berthold LB 9501 luminometer (measurement
time, 7.5 seconds).
Figure 1. SNP and SNAP repress mitogen-stimulated cdk2
kinase activity in VSMCs. A, Dose-dependent inhibition of cdk2-
mediated histone kinase activity by SNP. Indicated rat VSMC
cell extracts were immunoprecipitated with anti-cdk2 antibodies,
and kinase activity was assayed by using histone H1 as sub-
strate (see “Methods”). A representative blot is shown. Serum-
deprived, quiescent VSMCs (Q) or VSMCs that were serum
stimulated for 18 hours in the presence or absence of SNP were
analyzed for cdk2 histone kinase activity. B, Repression of cdk2
activity by SNP was maintained for 48 hours after serum stimu-
lation. The cdk2-dependent histone kinase activity was assayed
in extracts from quiescent rat VSMCs and from VSMCs stimu-
lated with serum for 18, 36, or 48 hours in the absence or pres-
ence of 300 mmol/L SNP. C, SNAP represses serum-stimulated
cdk2 kinase activity. The cdk2-mediated histone kinase activity
was assayed in extracts from quiescent or serum-stimulated
VSMCs (18 hours) in the absence or presence of 300 mmol/L
SNAP or SNP.
Selected Abbreviations and Acronyms
8-Br-cGMP 5 8-bromo-cyclic GMP
cdk 5 cyclin-dependent kinase
CRE 5 cAMP-responsive element
DMEM 5 Dulbecco’s modified Eagle’s medium
FBS 5 fetal bovine serum
NO 5 nitric oxide
PBS 5 phosphate-buffered saline
SDS 5 sodium dodecyl sulfate
SNAP 5 S-nitroso-N-acetylpenicillamine
SNP 5 sodium nitroprusside
VSMC 5 vascular smooth muscle cell
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Statistical Analysis
Results are expressed as mean6SEM. Statistical significance was
evaluated with an unpaired Student’s t test for comparisons
between two mean values and ANOVA followed by Scheffe´’s
procedure for more than two mean values. A value of P,.05 was
interpreted to denote statistical significance.
Results
NO Donors Repress Serum Induction of cdk2
Kinase Activity in VSMCs
We first examined the effect of SNP or SNAP on cdk2
kinase activity in cultures of rat VSMCs. Protein extracts
were prepared from cultures of serum-deprived VSMCs
and VSMCs stimulated with 10% FBS in the presence or
absence of NO donors. These extracts were immunopre-
cipitated with anti-cdk2 antibodies, and the kinase activity
of the immunopellets was assayed with histone H1 as
substrate. As shown in Fig 1A, cdk2 activity is markedly
induced in serum-stimulated VSMCs. This serum-depen-
dent increase in cdk2 activity after 18 hours of serum
stimulation was completely abrogated by the presence of
SNP in a dose-dependent manner. The repression by SNP
was sustained for up to 48 hours after serum induction (Fig
1B). Moreover, the NO donor SNAP also abrogated the
induction of cdk2 activity by serum (Fig 1C).
NO Donors Specifically Repress
Cyclin A Induction
Having demonstrated that NO donors repress cdk2 activity,
we performed a series of Western blot analyses to test the
effect of NO donors on the expression of cdk2 and its
regulatory subunits, cyclins E and A. As shown in Fig 2A,
either 10% FBS or 10% FBS plus SNP had no detectable
effect on the protein expression of cdk2, cyclin E, or the
control protein tubulin. In contrast, cyclin A protein levels
were markedly upregulated in serum-stimulated VSMCs,
and the inclusion of SNP abrogated this induction. The
effect of SNP on serum-stimulated cyclin A expression
was dose dependent (Fig 2B). The repression of cyclin A
by SNP was detected at 18 hours (Fig 2B) and at the 36-
and 48-hour time points after serum addition (not shown).
Similarly, SNP did not affect cdk2 or cyclin E expression
at any of these other time points. Finally, cyclin A
expression was also repressed by SNAP (Fig 2C). Similar
to SNP, SNAP did not affect cyclin E or cdk2 protein
levels. Thus, changes in the expression of cyclin A, an
activating subunit of cdk2, may contribute to NO-mediated
downregulation of cdk2 activity.
Figure 2. SNP represses serum-induced cyclin A expression in
rat VSMCs. A, Indicated extracts were subjected to Western
blot analysis using anti-cdk2, anti–cyclin A, anti–cyclin E, and
anti-tubulin antibodies as described in “Methods.” Representa-
tive blots are shown. Serum stimulation was for 18 hours in the
presence or absence of 300 mmol/L SNP. Q indicates serum-
deprived, quiescent VSMCs. B, Dose-dependent downregulation
of cyclin A protein expression by SNP. VSMCs were stimulated
with serum for 18 hours in the absence or presence of the indi-
cated amount of SNP. Extracts were subjected to Western blot
analysis as described in “Methods.” C, SNAP represses cyclin A
protein expression but has no effect on cyclin E or cdk2 protein
levels. Indicated extracts were subjected to Western blot analy-
sis using anti–cyclin A, anti-cdk2, or anti–cyclin E antibodies as
described in “Methods.” Rat VSMCs were stimulated with
serum for 18 hours in the presence or absence of 300 mmol/L
SNAP or 300 mmol/L SNP. Q indicates serum-deprived, quies-
cent VSMCs.
Figure 3. SNP and SNAP downregulates cyclin A mRNA.
Northern blot analysis was performed with 20 mg of total RNA.
The hybridization probe was human cyclin A cDNA. Ethidium
bromide stain of the 28S ribosomal RNA band in the gel after
transfer to membrane is shown to demonstrate uniformity in gel
loading and RNA integrity. RNA was extracted from quiescent,
serum-deprived rat VSMCs (Q) or VSMCs stimulated with serum
for 18 hours in the absence or presence of 300 mmol/L SNAP or
300 mmol/L SNP.
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SNP Represses Serum Induction of Cyclin A
Promoter Activity in VSMCs
Northern blot analyses were performed to determine
whether the repression of cyclin A by NO donors occurred
at the level of mRNA. As shown in Fig 3, cyclin A mRNA
was markedly upregulated by the addition of serum to
quiescent VSMCs, and the inclusion of SNP or SNAP
abrogated this induction. To test whether NO donor-
mediated suppression of cyclin A expression in serum-
stimulated VSMCs may be achieved at the transcriptional
level, we next performed transient transfection assays with
plasmids containing fragments of the human cyclin A
promoter fused to the luciferase reporter gene (Fig 4A).
The pulmonary arterial cell line PAC1 was used for these
studies because it is efficiently transfected with plasmid
DNA constructs.31 After transfection in serum-free me-
dium, PAC1 cells were switched to DMEM supplemented
with 0.5% FBS (quiescent cells) or serum-stimulated with
DMEM supplemented with 10% FBS with or without SNP,
SNAP, or 8-Br-cGMP. Cell extracts were prepared 20
hours later, and luciferase activity was measured. As
shown in Fig 4B, activity of the 2924/1245 cyclin A
promoter region is markedly upregulated by serum, and the
sequence spanning from 279 to 1100 is sufficient to
confer this regulation. However, the 254/1100 cyclin A
promoter fragment was not induced by serum. The addition
of SNP, SNAP, or 8-Br-cGMP prevented the serum-
dependent induction of cyclin A promoter activity. The
repression of the 279/1100 promoter construct by SNP
was dose dependent (Fig 4C). Treatment with serum or
with serum plus SNP, SNAP, or 8-Br-cGMP had little or
no effect on transcription from the Simian virus 40
promoter (Fig 4D).
Discussion
It is well documented that NO has an antiproliferative
effect on VSMC proliferation in vivo and in vitro.6 –13 The
inhibition of VSMC proliferation by NO is associated with
distinct cell cycle arrests in phases G1 and S.34 In the
present study, we examined the effects of SNP and SNAP
on the expression and activity of cdk2 and its regulatory
subunits, cyclins E and A.14,15 Treatment with these NO
donors prevented the serum induction of cdk2 activity in
VSMCs. We found that mitogen stimulation markedly
induced cyclin A expression, but cdk2 and cyclin E levels
remained constant. The serum induction of both cyclin A
mRNA and protein was abrogated by the inclusion of SNP
or SNAP, suggesting a reduction in cyclin A expression
can contribute to the NO-mediated decrease in cdk2
activity and VSMC growth arrest. Others have shown that
NO donors upregulate expression of the cdk inhibitor
p21,35 which may also contribute to VSMC growth
inhibition.
To test whether NO donors may limit VSMC growth
through transcriptional repression of the cyclin A gene, we
examined the effect of SNP and SNAP on cyclin A
promoter activity in immortalized PAC1 smooth muscle
cells. In agreement with previous studies in NIH 3T3
fibroblasts29 and VSMCs,36 our transient transfection as-
says demonstrated that serum-dependent regulation of the
cyclin A gene promoter in VSMCs is mediated by se-
quences extending from 279 to 1100 relative to the
predominant transcription start site. This promoter frag-
ment contains a CRE and an E2F-binding site that are
required for cell cycle–regulated expression of this pro-
moter in VSMC and nonmuscle cell types.36 –39 The 254/
1100 cyclin A promoter fragment, which contains the E2F
but not CRE site, is not sufficient for cyclin A promoter
transcription in serum-stimulated VSMCs. Similarly, this
construct is not induced by serum in bovine aortic endo-
thelial cells (I. Spyrodopoulos and D.W. Losordo, personal
communication, September 18, 1997). Thus, the E2F site
does not appear to be sufficient for serum stimulation of
cyclin A promoter activity in vascular cells. It has been
previously shown that the CRE is necessary for maximal
cyclin A promoter activity in serum-stimulated NIH 3T3
cells40 and human diploid fibroblasts induced by activation
of the adenylyl cyclase signaling pathway.41 Conversely,
this site also is involved in cyclin A promoter downregu-
lation in contact-inhibited endothelial cells38 and in trans-
forming growth factor-b–treated Chinese hamster lung
fibroblasts.41 Collectively, these results indicate that CRE-
dependent transcriptional regulation of cyclin A expres-
sion integrates both positive and negative cell growth
regulatory signals. Serum activation of either the 279/
1100 or 2924/1245 cyclin A promoter fragment was
repressed by the addition of SNP or SNAP, indicating that
NO functions as a negative regulator of cyclin A gene
transcription. Serum-induced expression of the cyclin A
promoter was also repressed by 8-Br-cGMP, as was
endogenous cyclin A expression and cdk 2 activity (not
shown). Further studies will be required to determine
whether cGMP mediates NO-dependent repression of cy-
clin A promoter activity.
Accumulating evidence indicates that cdk2 is a key
regulator of VSMC proliferation in vitro and in vivo. First,
cdk2 activity is induced after angioplasty in the rat carotid
artery,24 and abrogation of cdk2 function by antisense cdk2
oligonucleotides suppresses neointimal VSMC accumula-
tion.25,26 Second, integrin-mediated growth arrest of serum-
stimulated VSMCs in vitro is associated with downregu-
lation of cdk2 activity.42 Third, the antiproliferative effects
of the VSMC transcription factor Gax is mediated by the
downregulation of cdk2 activity.43 In the present study, we
show that the antiproliferative effect of NO donors is
associated with decreased cdk2 activity in serum-stimu-
lated VSMCs.
Suppression of cdk2 activity in SNP- and SNAP-treated
VSMCs correlated with reduced cyclin A protein and
mRNA levels, but SNP did not diminish cdk2 or cyclin E
protein expression. Similarly, inhibition of growth factor–
stimulated VSMC proliferation by polymerized collagen42
or by overexpression of the Gax transcription factor43
diminishes cyclin A protein levels but has no effect on
cdk2 or cyclin E protein expression. Collectively, these
results indicate that cyclin A may function at one of the
key regulatory points underlying integrin-, Gax-, and
NO-mediated antiproliferative effects in VSMCs.
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In summary, the results of the present study suggest a
mechanism by which repression of cyclin A gene tran-
scription contributes to NO-mediated downregulation of
cdk2 activity and, ultimately, VSMC growth arrest. Eluci-
dation of the networks underlying the regulation of cyclin
A gene expression by NO may permit the development of
new strategies to inhibit the proliferative response of
VSMCs to arterial injury.
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Figure 4. SNP represses serum
induction of cyclin A promoter activity
in PAC1 VSMCs. A, Schematic of the
reporter constructs used for the anal-
ysis of cyclin A promoter activity.
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and E2F transcription factors, which
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moter. B, PAC1 smooth muscle cells
were transfected with cyclin A–lucif-
erase reporter genes containing the
indicated promoter fragments from
the human cyclin A gene. Cells were
transiently cotransfected in serum-
free media with 2 mg of the indicated
reporter gene construct and 1 mg of
the pSV2-AP plasmid. After transfec-
tion, cells were maintained in 0.5%
FBS/DMEM (Q indicates quiescent),
10% FBS/DMEM (SS indicates serum
stimulation), 10% FBS/DMEM with
the indicated amount of SNP
(SS1SNP), 10% FBS/DMEM with
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were prepared 20 hours later for the
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is expressed relative to the alkaline
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cotransfected pSV2-AP plasmid to
control for differences in transfection
efficiencies. Results show the
mean6SEM of three transfections.
For the 2924/1245 and 279/1100
promoter constructs, the differences
between SS and SS1SNAP,
SS1SNP, or SS18-Br-cGMP groups
are statistically significant (all P,.05).
C, Repression of cyclin A promoter
activity by SNP is dose dependent.
Cells were transfected with the 279/
1100 cyclin A promoter construct as
described in B. Serum-stimulated
(SS) cells were incubated in the
absence or presence of the indicated
amount of SNP. Results show the
mean6SEM of three transfections.
The differences between SS and the
SS1SNP (100 mmol/L) or SS1SNP
(300 mmol/L) groups are statistically
significant (P,.05 and P,.005,
respectively). D (facing page), Simian virus 40 promoter activity is not affected by serum, SNP, SNAP, or 8-Br-cGMP. PAC1 cells were
transfected with the pSV2-AP plasmid, which contains the alkaline phosphatase cDNA under the control of the Simian virus 40 promot-
er/enhancer. Transfected cells were serum deprived (Q) or serum stimulated in the absence or presence of the indicated amount of
SNP, SNAP, or 8-Br-cGMP as described in B. Results show the mean6SEM of nine transfections. The differences between groups are
not significant by ANOVA (P5.74).
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